ArticleFrontiers in medicine2025
Clinical efficacy and predictive factors of photodynamic therapy combined with recombinant mussel mucin repair dressing in treating post-inflammatory hyperpigmentation.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy and safety of photodynamic therapy (PDT) combined with recombinant mussel mucin repair dressing in treating post-inflammatory hyperpigmentation (PIH), and to assess its impact on patient quality of life. Methods: In a prospective, controlled, non-randomized clinical study, we enrolled 310 patients (Fitzpatrick III-IV) with epidermal or dermal PIH. Patients underwent PDT by wavelength and energy protocol, followed by immediate application of recombinant mussel mucin repair dressing. Pigmentation area, melanin density, adverse events, recurrence, and quality of life were assessed over 14 months. Results: The combined therapy achieved significantly greater pigment clearance at 4 weeks (42.3 vs. 25.6% in controls, Conclusion: PDT combined with recombinant mussel mucin repair dressing provides superior pigment clearance, reduced recurrence, improved safety, and enhanced quality of life compared with standard therapy. This multimodal approach offers a promising option for PIH management in darker skin types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.